Transce3nd’s Roivant Sciences ROIV Stock Holding History

Transce3nd’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-454	Closed	-$5.12K	–	919
2025 Q2	$5.12K	Hold	454	–	–	﹤0.01%	737
2025 Q1	$4.58K	Buy	454 +3	+0.7%	+$32	﹤0.01%	745
2024 Q4	$5.33K	Buy	+451	New	+$5.33K	﹤0.01%	912

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Transce3nd's ROIV Position: Q3 2025 in Review

Transce3nd sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 454 shares — an estimated $5.12K sold.

Transce3nd first reported a position in ROIV in Q4 2024 and held it in 3 quarters. The position peaked at $5.33K in Q4 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

Transce3nd reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 454 Roivant Sciences shares in Q3 2025, an estimated $5.12K.
Transce3nd first reported a position in Roivant Sciences in Q4 2024 and held it in 3 quarters.
Transce3nd's Roivant Sciences position peaked at $5.33K in Q4 2024.
337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.